Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(24):1851-1852; doi:10.1093/jnci/dji433
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Jansen, M. P. H. M.
Right arrow Articles by Berns, E. M. J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jansen, M. P. H. M.
Right arrow Articles by Berns, E. M. J. J.
Related Collections
Right arrowResponse to this Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

CORRESPONDENCE

Re: Limits of Predictive Models Using Microarray Data for Breast Cancer Clinical Treatment Outcome

Maurice P. H. M. Jansen, John A. Foekens, Jan G. M. Klijn, Els M. J. J. Berns

Affiliation of authors: Department of Medical Oncology, Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam, The Netherlands

Correspondence to: Els Berns, PhD, Erasmus MC, Josephine Nefkens Institute, Rm. Be424, Department of Medical Oncology, PO Box 1738, 3000 DR Rotterdam, The Netherlands (e-mail: p.berns@erasmusmc.nl).

The first 10% of the full text of this article appears below.

The ability to accurately predict outcome to tamoxifen therapy would advance the management of breast cancer. Tamoxifen acts through the estrogen receptor (ER), and ER expression levels are currently the best predictors of response. Last year, Ma et al. (1) reported a novel biomarker of a two-gene expression ratio (HOXB13 to IL17BR) in 60 patients with ER-positive early-stage breast cancer treated with adjuvant tamoxifen. However, recently, Reid . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Response to this Correspondence

RESPONSE: Re: Limits of Predictive Models Using Microarray Data for Breast Cancer Clinical Treatment Outcome
James F. Reid, Lara Lusa, Loris De Cecco, Danila Coradini, Silvia Veneroni, Maria Grazia Daidone, Manuela Gariboldi, and Marco A. Pierotti
J Natl Cancer Inst 2005 97: 1852-1853. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
Z. Wang, S. Dahiya, H. Provencher, B. Muir, E. Carney, K. Coser, T. Shioda, X.-J. Ma, and D. C. Sgroi
The Prognostic Biomarkers HOXB13, IL17BR, and CHDH Are Regulated by Estrogen in Breast Cancer
Clin. Cancer Res., November 1, 2007; 13(21): 6327 - 6334.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. P.H.M. Jansen, A. M. Sieuwerts, M. P. Look, K. Ritstier, M. E. Meijer-van Gelder, I. L. van Staveren, J. G.M. Klijn, J. A. Foekens, and E. M.J.J. Berns
HOXB13-to-IL17BR Expression Ratio Is Related With Tumor Aggressiveness and Response to Tamoxifen of Recurrent Breast Cancer: A Retrospective Study
J. Clin. Oncol., February 20, 2007; 25(6): 662 - 668.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. P. Goetz, J. N. Ingle, F. J. Couch, C. Fan, L. J. van't Veer, and C. M. Perou
Gene-Expression-Based Predictors for Breast Cancer
N. Engl. J. Med., February 15, 2007; 356(7): 752 - 753.
[Full Text] [PDF]

Home page
 JCOHome page
X.-J. Ma, S. G. Hilsenbeck, W. Wang, L. Ding, D. C. Sgroi, R. A. Bender, C. K. Osborne, D. C. Allred, and M. G. Erlander
The HOXB13:IL17BR Expression Index Is a Prognostic Factor in Early-Stage Breast Cancer
J. Clin. Oncol., October 1, 2006; 24(28): 4611 - 4619.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. F. Symmans
Genomic testing for sensitivity of breast cancer to hormonal therapy.
Clin. Cancer Res., April 1, 2006; 12(7): 1954 - 1955.
[Full Text] [PDF]